An antimetabolite (azathioprine, 6 - mercaptopurine, or methotrexate), an anti-tumor necrosis factor (TNF) agent (infliximab, adalimumab, or certolizumab pegol), or a combination of both, can be used as 2nd-line therapy after corticosteroids, and even as first-line therapy in preference to corticosteroids.